Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.000.81%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 299.12% | -5.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 299.12% | -5.87% |
| Cost of Revenue | -- | -- | -- | 67.49% | -- |
| Gross Profit | -- | -- | -- | 188.17% | -- |
| SG&A Expenses | -17.26% | 33.48% | -2.97% | -49.65% | -40.19% |
| Depreciation & Amortization | -- | -- | -- | -18.25% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.26% | 33.48% | -2.97% | -47.11% | -66.98% |
| Operating Income | 17.26% | -33.48% | 2.97% | 65.33% | 38.65% |
| Income Before Tax | -0.35% | -631.17% | -413.27% | -3,014.33% | 79.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.35% | -631.17% | -413.27% | -3,014.33% | 79.79% |
| Earnings from Discontinued Operations | -- | 814.34% | 58.34% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.45% | 920.66% | -4.50% | -3,014.33% | 51.19% |
| EBIT | 17.26% | -33.48% | 2.97% | 65.33% | 38.65% |
| EBITDA | 38.22% | -73.13% | 4.41% | 74.24% | 59.29% |
| EPS Basic | 99.80% | 86.05% | 77.78% | 33.91% | 81.28% |
| Normalized Basic EPS | 99.07% | -106.05% | -151.31% | -566.32% | 95.64% |
| EPS Diluted | 99.80% | 86.05% | 77.78% | 33.91% | 81.28% |
| Normalized Diluted EPS | 99.07% | -106.05% | -151.31% | -566.32% | 95.64% |
| Average Basic Shares Outstanding | 10,653.94% | 8,672.42% | 510.51% | 325.13% | 363.68% |
| Average Diluted Shares Outstanding | 10,653.94% | 8,672.42% | 510.51% | 325.13% | 363.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |